Natco Pharma Explores ₹2,000 Crore Capital Raise Alongside Q1 Results

Q1 FY27 Consolidated Results YoY: Revenue from operations at 735 Cr vs 1329 Cr, down 44.7%, largely due to lower Lenalidomide revenue, partially offset by base-business growth. EBITDA at 246 Cr vs 633 Cr, down 61.2%. EBITDA Margin at 33.4% vs 47.6%, contraction of 1420bps; employee costs grew 6.1% despite revenue declining 44.7%. PAT at 207 Cr vs 480 Cr, down 57.0%. Pharmaceuticals revenue declined 46.3% while Agro chemicals grew 17.6%, though Agro remained loss-making at 5.3 Cr. Board declared an interim dividend of Rs 1.50 per share and is evaluating a fundraise of up to 2000 Cr through equity or other securities.